Navigation Links
Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets
Date:8/24/2009

PRINCETON, N.J., Aug. 24 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Robinul(R) 1 mg and Robinul(R) Forte Tablets, 2 mg, respectively, of Sciele Pharma, Inc. Total annual market sales for Glycopyrrolate Tablets were $26 million (IMS - MAT: June 2009). Glycopyrrolate Tablets are indicated for use as adjunctive therapy in the treatment of peptic ulcer.

"We are pleased to receive this final approval for Glycopyrrolate Tablets. This product formulation will be launched in the October - December quarter to all classes of trade and further expands the number of affordable generic product formulations offered by RPI, that will be of benefit to patients, healthcare professionals and the U.S. healthcare system," according to Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries. Ranbaxy is a subsidiary of Daiichi Sankyo Company, Ltd.

*Robinul(R) is a registered trademark of Sciele Pharma, Inc.

    CONTACTS:  Charles M. Caprariello
               Vice President, Corporate Communications
               Ranbaxy Inc.
               (609) 720-5615

               Edwige Buteau
               RF Binder Partners Inc.
               (212) 994-7517

               Andrea Pavone
               RF Binder Partners Inc.
               (212) 994-7568


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
2. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
3. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
4. Ranbaxy Receives Tentative Approval For Valsartan Tablets
5. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
6. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
7. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
8. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
9. Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
10. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
11. Press Statement Issued by Ranbaxy Laboratories Limited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Arizona (PRWEB) , ... December 07, 2016 , ... Delete® ... Just in Time For The Holiday Party Season. Save Up To 33% Off Botox® ... Laser Salon is providing the Phoenix Valley with Delightful Deals on Botox® ...
(Date:12/7/2016)... ... , ... The medical profession is well aware that heart attacks do indeed ... heart attacks among 138,602 people recorded a 35% higher number of heart attacks in ... of course–no time of year is a good time for a heart attack! In ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... medicine device WellnessPro Plus for consumers and healthcare professionals to manage chronic ... by expanding the treatment modalities available in a single device. The announcement ...
(Date:12/7/2016)... ... 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief but ... presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of published ... for this country. , Nancy attributes her patriotic nature to her WWII veteran father. ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... ... individuals impacted by cerebral cavernous angiomas, was awarded a grant from the Julian ... engagement program. New Mexico has more people with cavernous angioma than anywhere in ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Homozygous Familial Hypercholesterolemia (HoFH) - ... Global Markets Direct,s latest Pharmaceutical and Healthcare ... – Pipeline Review, H2 2016, provides an ... (Metabolic Disorders) pipeline landscape. Homozygous familial ... caused due to mutation from both parents. ...
(Date:12/6/2016)... The pen needles market is projected to reach USD ... 2016, growing at a CAGR of 11.2% during the ... years, the pen needles market has witnessed various technological ... for safety injections in the healthcare industry. These advancements ... with an aim to reduce pain, increase comfort, and ...
(Date:12/6/2016)... 2016   AlloSource , one of the ... and soft-tissue allografts for use in surgical procedures, ... for being named to the Board of Examiners ... by the Commerce Department,s National Institute of Standards ... process excellence. The Baldrige Award is the nation,s ...
Breaking Medicine Technology: